Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News and Views
Nature Chemical Biology 2, 63–64 (1 February 2006) | doi:10.1038/nchembio0206-63
Inhibitors of Bcr-abl... breaking new ground again
&
Abstract
The clinical success of imatinib (STI-571, Gleevec), a potent and selective inhibitor of the fusion protein Bcr-abl, for use in the treatment of chronic myelogenous leukemia (CML) heralded a new era of targeted molecular medicines. The ability of cancer cells to outsmart the new generation of customized drugs is reflected in the high incidence of resistance to imatinib that often develops in patients with advanced CML.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
